SG Americas Securities LLC Acquires 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX

SG Americas Securities LLC boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 785.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 134,530 shares of the company’s stock after buying an additional 119,339 shares during the quarter. SG Americas Securities LLC’s holdings in Neurocrine Biosciences were worth $19,080,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. AQR Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares during the last quarter. Norges Bank acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $122,278,000. JPMorgan Chase & Co. raised its stake in Neurocrine Biosciences by 11.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock valued at $664,019,000 after acquiring an additional 468,405 shares during the period. Two Sigma Investments LP acquired a new stake in Neurocrine Biosciences during the 3rd quarter valued at $48,791,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Neurocrine Biosciences during the 2nd quarter valued at $42,933,000. Institutional investors own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $128.32 on Friday. The firm has a 50-day moving average of $131.96 and a 200-day moving average of $139.52. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18. The stock has a market cap of $12.88 billion, a PE ratio of 27.54, a PEG ratio of 0.69 and a beta of 0.32.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.Neurocrine Biosciences’s revenue was up 28.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.69 earnings per share. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wolfe Research began coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price objective on the stock. Wedbush lifted their target price on shares of Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Mizuho upped their price target on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. UBS Group lowered their price target on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Zacks Research downgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.10.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.